Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Back to Forecasting
KVUE Forecast Markets
Kenvue Inc.
7
Active Markets
52%
Avg Probability
All Markets
7 markets
Will there be an adverse court ruling in the Tylenol/acetaminophen MDL by December 31, 2026?
38%
Likely No
92% agreement
Jan 15, 2027
IG: 0.80
Will the FTC require divestitures or impose conditions on the K-C/KVUE merger?
42%
Likely No
90% agreement
Jan 15, 2027
IG: 0.64
Will the Kimberly-Clark/Kenvue merger close by December 31, 2026?
72%
Likely Yes
94% agreement
Jan 15, 2027
IG: 0.60
Will Kenvue report FY2025 organic sales decline worse than -4%?
30%
Likely No
92% agreement
Apr 30, 2026
IG: 0.48
Will KVUE stock price trade above $20 per share by June 30, 2026?
62%
Likely Yes
94% agreement
Jul 5, 2026
IG: 0.48
Will Tylenol maintain its U.S. OTC analgesics market share leadership through Q2 2026?
88%
Likely Yes
96% agreement
Aug 31, 2026
IG: 0.36
Will Kenvue's net tariff impact exceed $100M in FY2025 after mitigation efforts?
32%
Likely No
94% agreement
Apr 30, 2026
IG: 0.36
Resolution Timeline
Apr 30, 2026
Will Kenvue's net tariff impact exceed $100M in FY2025 after mitigation efforts?Prediction: 32%
Aug 31, 2026
Will Tylenol maintain its U.S. OTC analgesics market share leadership through Q2 2026?Prediction: 88%
Jan 15, 2027
Will there be an adverse court ruling in the Tylenol/acetaminophen MDL by December 31, 2026?Prediction: 38%
Jan 15, 2027
Will the FTC require divestitures or impose conditions on the K-C/KVUE merger?Prediction: 42%